Phase 3 RCT in 2,109 patients with high-risk localised prostate cancer having prostatectomy: perioperative apalutamide plus ADT raised pCR/minimal residual disease (8.9% vs 1.0%) and 5-year MFS (78.2% vs 73.5%; HR 0.80) vs placebo; grade 3-4 AEs 39.6% vs 31.0%.
RCTn = 2,109
Taplin et al. Perioperative Apalutamide in High-Risk Localized Prostate Cancer